



Advances in Immunotherapy for T Cells and Tumors

Guest Editor:

Dr. Zhichen Sun
UT Southwest Medical Center,
Dallas, TX, USA

Deadline for manuscript
submissions:

15 March 2025

Message from the Guest Editor

Cancer is a devastating disease which has been and continues to be one of the main threats to human health. Traditional cancer treatments, including surgery, chemotherapy, and radiation therapy, have demonstrated very limited efficacy for patients with late-stage disease. In addition, chemotherapy and radiotherapy often cause considerable side effects. Therefore, innovative and effective cancer treatments are urgently needed for cancer patients with late-stage and refractory disease. Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broad variety of hematological and solid malignancies.

This Special Issue welcomes reviews, as well as original articles related to research on a broad range of immunotherapy treatments, including cellular therapies, vaccines, and ICB; the identification of new predictive biomarkers and therapeutic targets; novel therapeutic approaches; and the use of immune modulators to overcome immune resistance, among others.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com